- Reuters•12 hours ago
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver ...
- Business Wire•3 days ago
Bristol-Myers Squibb’s BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial
Bristol-Myers Squibb Company today announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 , a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis .
- Reuters•3 days ago
Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday. NASH, a progressive fatty liver disease tied to obesity and diabetes, afflicts about 5 percent of the population and is poised to become the leading cause of liver transplants. The 16-week, 74-patient trial tested the subcutaneously-injected drug, BMS-986036, at two dosing regimens versus placebo in adults whose NASH was confirmed by liver biopsy.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||53.51 - 54.00|
|52 Week Range||46.01 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.21|
|Dividend & Yield||1.56 (2.95%)|
|1y Target Est||N/A|